Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores

Claus F. Vogelmeier*, Klaus F. Rabe, Surya P. Bhatt, Nicola A. Hanania, Mona Bafadhel, Stephanie A. Christenson, Alberto Papi, Dave Singh, Elizabeth Laws, Jennifer Maloney, Paula Dakin, Xin Lu, Deborah Bauer, Ashish Bansal, Lacey B. Robinson, Raolat M. Abdulai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index predicts 5-year mortality risk in chronic obstructive pulmonary disease (COPD); higher scores predict worse outcomes. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4/13, reduced exacerbations and improved lung function in patients with COPD in the phase 3 BOREAS trial (NCT03930732). We assessed dupilumab efficacy in patients with COPD and type 2 inflammation by baseline BODE index. Methods: Patients with COPD, moderate-to-severe airflow limitation, screening blood eosinophils ≥300 cells/μL, and high exacerbation risk, on triple therapy, received 300 mg add-on dupilumab or placebo every 2 weeks for 52 weeks. Annualized moderate or severe COPD exacerbation rate and change from baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV1) at Weeks 12 and 52 were assessed by baseline BODE index, categorized as low (≤4) or high (>4). Results: Of 934 patients with reported baseline BODE index scores (dupilumab: 470; placebo: 464), 61.8 % had scores ≤4. Dupilumab reduced exacerbations versus placebo, regardless of baseline BODE index group. Exacerbation reductions were similar by BODE index group; relative risk (95 % confidence interval) for patients with BODE index >4 versus ≤4 was 0.656 (0.496–0.868) versus 0.718 (0.547–0.944). At Weeks 12 and 52, dupilumab consistently improved pre-bronchodilator FEV1 versus placebo, regardless of baseline BODE index group. Conclusion: Dupilumab reduced exacerbations and improved lung function in patients with COPD and type 2 inflammation irrespective of baseline BODE index score. Clinical trial registration number: BOREAS trial NCT03930732.

Original languageEnglish
Article number108015
JournalRespiratory medicine
Volume241
DOIs
Publication statusPublished - May 2025

Keywords

  • BODE index
  • COPD
  • Dupilumab
  • Exacerbations
  • Lung function
  • Type 2 inflammation

Fingerprint

Dive into the research topics of 'Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores'. Together they form a unique fingerprint.

Cite this